Stannsoporfin (INH-001)
Prevention of severe hyperbilirubinemia in newborns
Phase 3Development
Key Facts
Indication
Prevention of severe hyperbilirubinemia in newborns
Phase
Phase 3
Status
Development
Company
About Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a public company traded on the OTC market, develops, manufactures, and commercializes specialty pharmaceutical products for severe and critical conditions. Its core business revolves around branded therapeutics like Acthar Gel and Ofirmev, alongside generic products. The company has undergone a major financial restructuring to address legacy liabilities and is now focused on stabilizing its commercial portfolio and advancing its development pipeline in autoimmune and inflammatory diseases.
View full company profile